Y Intercept Hong Kong Ltd Has $6.41 Million Stake in Encompass Health Corporation $EHC

Y Intercept Hong Kong Ltd trimmed its stake in Encompass Health Corporation (NYSE:EHC) by 29.9% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 66,215 shares of the company’s stock after selling 28,247 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Encompass Health were worth $6,405,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. increased its stake in shares of Encompass Health by 3,059,159.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock worth $402,640,000 after purchasing an additional 3,793,358 shares during the period. AlphaCore Capital LLC acquired a new position in shares of Encompass Health in the fourth quarter valued at $4,881,000. Tudor Investment Corp ET AL lifted its holdings in shares of Encompass Health by 155.3% during the 3rd quarter. Tudor Investment Corp ET AL now owns 210,712 shares of the company’s stock worth $26,765,000 after acquiring an additional 128,191 shares during the period. SG Americas Securities LLC boosted its holdings in Encompass Health by 1,070.9% during the fourth quarter. SG Americas Securities LLC now owns 88,054 shares of the company’s stock valued at $9,346,000 after purchasing an additional 80,534 shares in the last quarter. Finally, Cinctive Capital Management LP boosted its stake in Encompass Health by 48.6% in the 3rd quarter. Cinctive Capital Management LP now owns 66,898 shares of the company’s stock valued at $8,497,000 after buying an additional 21,887 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on EHC shares. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. TD Cowen initiated coverage on Encompass Health in a report on Thursday, May 28th. They set a “buy” rating and a $125.00 target price on the stock. Weiss Ratings lowered Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, June 26th. Leerink Partners set a $152.00 price target on Encompass Health in a report on Friday, May 22nd. Finally, Barclays decreased their price objective on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a report on Tuesday, May 5th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.86.

Insiders Place Their Bets

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of Encompass Health stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the transaction, the executive vice president owned 24,755 shares of the company’s stock, valued at approximately $2,588,382.80. The trade was a 2.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 1.80% of the company’s stock.

Encompass Health Trading Up 0.0%

NYSE EHC opened at $106.48 on Friday. Encompass Health Corporation has a 12 month low of $92.77 and a 12 month high of $127.99. The stock has a 50-day simple moving average of $103.10 and a 200 day simple moving average of $103.43. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $10.56 billion, a PE ratio of 17.78, a P/E/G ratio of 2.32 and a beta of 0.74.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.09. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The firm had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the previous year, the company earned $1.37 earnings per share. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Research analysts forecast that Encompass Health Corporation will post 5.97 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Wednesday, July 1st will be issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, July 1st. Encompass Health’s dividend payout ratio (DPR) is 12.69%.

About Encompass Health

Encompass Health Corporation is a leading provider of post?acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end?of?life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.